A5014144775- Cytokine Signaling Pathways and Interactions
- Cancer Mechanisms and Therapy
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Toxin Mechanisms and Immunotoxins
- Biochemical and Molecular Research
- Hippo pathway signaling and YAP/TAZ
- interferon and immune responses
- Cancer-related Molecular Pathways
- Cancer, Lipids, and Metabolism
- Liver Disease Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
The First Affiliated Hospital, Sun Yat-sen University
2023-2024
Sun Yat-sen University
2023-2024
Objective Whether and how the PI3K-AKT pathway, a central node of metabolic homeostasis, is responsible for high-fat-induced non-alcoholic steatohepatitis (NASH) hepatocellular carcinoma (HCC) remain mystery. Characterisation AKT regulation in this setting will provide new strategies to combat HCC. Design Metabolite library screening disclosed that palmitic acid (PA) could activate AKT. In vivo vitro palmitoylation assay were employed detect palmitoylation. Diverse cell mouse models,...
Abstract The PI3K–AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. Although inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry–based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT undergoes...
Physiologically, FoxA1 plays a key role in liver differentiation and development, pathologically exhibits an oncogenic prostate breast cancers. However, its upstream regulation tumorigenesis remain unclear. Here, we demonstrate that acts as tumor suppressor cancer. Using CRISPR-based kinome screening approach, noncanonical inflammatory kinase IKBKE has been identified to inhibit transcriptional activity. Notably, directly binds phosphorylates reduce complex formation DNA interaction, leading...
<p>Including supplementary figure S1-9</p>
<p>Including supplementary figure S1-9</p>
<div>Abstract<p>The PI3K-AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. While inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry-based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT...
<div>Abstract<p>The PI3K–AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. Although inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry–based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds...
<div>Abstract<p>The PI3K-AKT signaling pathway is frequently dysregulated in cancer, and it hyperactivated approximately 50% of breast cancers. While inhibitors directly targeting the axis have been developed, clinical efficacy has limited to only a subset patients. Identification mechanisms underlying AKT-driven tumorigenesis could lead alternative approaches block suppress tumor growth. Mass spectrometry-based analyses demonstrated that salt-inducible kinase 1 (SIK1) binds AKT...
<p>Including supplementary figure S1-9</p>
<p>Including supplementary figure S1-9</p>